ACT50

ACT50 is an investigational recombinant protein therapeutic being developed by Xiamen Amoytop Biotech for the treatment of tumor-related diseases and conditions involving neo-angiogenesis. As part of Amoytop's pipeline, which focuses on long-acting biologics, ACT50 likely utilizes the company's proprietary Y-shape PEGylation technology to enhance its pharmacokinetic profile and extend its therapeutic half-life. The drug is designed to inhibit the formation of new blood vessels (angiogenesis) that facilitate tumor growth and metastasis. It is currently in the early stages of development, specifically within the pharmaceutical research and preclinical phase.